Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA Exposure in Peripheral Blood Using a Novel Process: A Feasibility Study

NCT03517332 is registered in ClinicalTrials.gov with Quantgene Inc. as lead sponsor.

NCT NCT03517332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03517332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA Exposure in Peripheral Blood Using a Novel Process: A Feasibility Study
Lead sponsor
Quantgene Inc.
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2015
Completion date
December 31, 2019
Enrollment
10,000 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical cancer, bladder cancer, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, other cancer, ovarian cancer, pancreatic adenocarcinoma